Insulin delivery devices market seen reaching $40.45 billion by 2030

The market for insulin pens, syringes, pumps and injectors is projected to grow from $26.14 billion in 2026 to $40.45 billion by 2030, driven by rising diabetes prevalence and demand for connected, minimally invasive care. North America led the market in 2025, while Asia-Pacific ranked second.

Why it matters: - Insulin delivery devices are central to diabetes care because they help patients manage blood glucose with precise dosing. - Strong market growth points to rising demand for easier-to-use, home-based, and connected treatment options. - The forecast suggests manufacturers and healthcare providers will face increasing pressure to support automated and minimally invasive insulin delivery.

What happened: - The insulin pens, syringes, pumps and injectors market is forecast to rise from $26.14 billion in 2026 to $40.45 billion by 2030. - The projection implies a 11.5% compound annual growth rate over the forecast period. - The market had been expected to grow from $23.52 billion in 2025 to $26.14 billion in 2026, equal to an 11.1% CAGR in that period. - North America was the largest regional market in 2025. - Asia-Pacific ranked as the second-largest regional market in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The details: - The market's historical growth has been linked to rising diabetes prevalence, broader use of insulin therapy, growth in homecare treatment models, wider availability of disposable delivery devices and stronger patient self-management. - Expected growth through 2030 is tied to greater adoption of connected diabetes devices, automated insulin delivery solutions, digital diabetes management platforms, wearable insulin technologies and minimally invasive methods. - Emerging trends include smart insulin delivery devices, patch and tubeless pumps, home-based management, connected insulin monitoring systems and a stronger focus on patient convenience. - Insulin pens, syringes, pumps and injectors can be reusable or disposable. - These devices are designed to deliver precise insulin doses directly into the bloodstream. - A free sample of the report is available here. - The full report is available here.

Between the lines: - Rising diabetes prevalence remains the clearest demand driver, especially as sedentary lifestyles and calorie-dense diets continue to contribute to obesity and insulin resistance. - The April 2025 International Diabetes Federation data on China highlights the scale of the challenge, with about 1.07 billion adults and a 11.9% diabetes prevalence rate, or nearly 148 million adult cases. - The market's emphasis is shifting from basic delivery hardware toward connected, software-enabled and more convenient systems. - That shift suggests competition may increasingly center on patient experience, data integration and automation rather than only on device access.

What's next: - Market growth is expected to continue as digital diabetes tools and wearable insulin technologies gain broader adoption. - Patch and tubeless pumps are likely to expand as patients and providers look for less invasive treatment options. - Companies active in this market will likely keep investing in connected monitoring and automated delivery features.

The bottom line: - Insulin delivery devices remain a high-growth diabetes care category, with long-term demand supported by rising patient numbers and a move toward smarter, more convenient treatment systems.